Peficitinib CAS 944118 01 8 Sales

Peficitinib CAS 944118 01 8 Sales Market Outlook

The global Peficitinib CAS 944118 01 8 market is projected to reach approximately USD 2 billion by the year 2035, exhibiting a compound annual growth rate (CAGR) of around 12% over the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of autoimmune diseases, which has significantly spurred the demand for effective treatments. Furthermore, advancements in pharmaceutical research and development have led to the introduction of innovative drug formulations and delivery methods, thereby enhancing the therapeutic efficacy of Peficitinib. The growing amount of funding for healthcare and pharmaceutical sectors, along with a rise in patient awareness regarding available treatment options, are additional factors driving the market expansion. As more healthcare providers recognize the benefits of Peficitinib in managing chronic conditions, the market is expected to experience substantial growth in both established and emerging regions.

Growth Factor of the Market

The growth of the Peficitinib market is primarily influenced by the escalating incidence of autoimmune diseases, particularly rheumatoid arthritis, which affects millions of individuals worldwide. The increasing adoption of biologics and targeted therapies among healthcare professionals has revolutionized the treatment landscape, favorably positioning Peficitinib due to its minimal side effects compared to conventional therapies. Furthermore, the rise in geriatric populations, who are more susceptible to autoimmune disorders, is likely to contribute to increased drug consumption. Improvements in diagnostic technologies and the growing number of specialty clinics focusing on autoimmune diseases play essential roles in reshaping the market dynamics, enabling quicker diagnosis and treatment initiation. Additionally, the ongoing research for new indications of Peficitinib is expected to broaden its application spectrum, providing further traction for market growth.

Key Highlights of the Market

• Projected global market size of approximately USD 2 billion by 2035.
• Estimated CAGR of around 12% between 2025 and 2035.
• Increasing prevalence of autoimmune diseases driving demand for Peficitinib.
• Advancements in drug formulation technology enhancing therapeutic efficacy.
• Expanding awareness among patients regarding treatment options boosting market growth.

By Product Type

Tablet :

Tablets are one of the most common forms of administering Peficitinib, providing a convenient and precise dosing option for patients. They offer significant benefits such as extended shelf life and ease of storage, which make them patient-friendly. Additionally, the tablet form allows for controlled release of the active ingredient, which can enhance absorption and overall efficacy. The ease of oral administration is particularly appealing to patients who may have difficulty with injections or other forms of medication delivery. Furthermore, the consistent demand for tablet formulations is expected to contribute to their dominant share in the market, as they remain a favored choice among healthcare professionals due to their simplicity and established nature in therapeutic regimes.

Capsule :

Capsules represent another significant product type within the Peficitinib market, offering a distinct alternative to tablets. One of the primary advantages of capsule formulations is their ability to mask the taste of the medication, thereby improving patient compliance, especially in populations sensitive to oral medications’ flavors. Capsules also allow for various release mechanisms, such as immediate or sustained release, which can be advantageous in managing the pharmacokinetics of Peficitinib. The convenience of capsule packaging enhances portability for patients, facilitating adherence to prescribed treatment regimens. Moreover, the rising popularity of capsule formulations in recent years has contributed to their growing market share, driven by both patient preference and clinical effectiveness.

Injection :

Injectable Peficitinib is an increasingly important product type, particularly in the context of acute disease management or for patients with severe autoimmune disorders requiring rapid therapeutic action. Injectables allow for direct entry of the medication into the bloodstream, providing quicker onset of action compared to oral formulations. This route of administration is often preferred for patients who have difficulty swallowing tablets or capsules, and those who require precise dosing that may not be achievable with oral forms. Furthermore, advancements in injectable technology, such as auto-injectors and pre-filled syringes, have improved the convenience and safety of administration, leading to greater acceptance among patients and healthcare providers alike.

Liquid :

Liquid formulations of Peficitinib cater to specific patient demographics, particularly pediatric and geriatric populations who may face challenges with solid oral dosage forms. Liquid medications are easier to swallow and can be more accurately dosed for children, thereby enhancing treatment compliance. The versatility of liquid formulations allows them to be used in various settings, including outpatient care, hospitals, and home healthcare. Moreover, the development of flavored liquid formulations can further improve patient acceptance, making it easier for individuals to adhere to their treatment plans. As the market continues to evolve, liquid Peficitinib formulations are expected to capture a notable share, particularly among patients needing tailored dosing options.

By Application

Rheumatoid Arthritis :

Peficitinib has emerged as a targeted therapy for rheumatoid arthritis, a chronic inflammatory disorder that affects millions globally. The drug's ability to inhibit Janus kinase (JAK) pathways offers significant therapeutic benefits in managing symptoms and slowing disease progression. This application is expected to dominate the market, driven by the high prevalence of rheumatoid arthritis and the unmet need for effective treatment options. With the increasing awareness regarding the benefits of early intervention, healthcare providers are more inclined to prescribe Peficitinib, especially for patients who exhibit resistance to traditional therapies. The efficacy and safety profile of Peficitinib continue to bolster its acceptance among rheumatologists, propelling its demand within this application segment.

Psoriatic Arthritis :

Peficitinib is also gaining traction in the treatment of psoriatic arthritis, a complex autoimmune condition characterized by joint inflammation and skin lesions. The drug's JAK-inhibiting properties make it an effective choice for managing the multifaceted symptoms associated with this condition. As more clinical trials demonstrate the benefits of Peficitinib in alleviating both joint and skin manifestations, the market for psoriatic arthritis applications is projected to grow significantly. Increased advocacy and educational efforts aimed at increasing awareness of psoriatic arthritis will further drive demand for targeted therapies like Peficitinib. The strategic focus of pharmaceutical companies on expanding treatment options for psoriatic arthritis is expected to enhance Peficitinib's market presence in this application.

Ulcerative Colitis :

Ulcerative colitis represents another crucial application for Peficitinib, as it is a prevalent inflammatory bowel disease that requires effective management strategies. The drug's mechanism of action allows for significant reduction of inflammation and promotes mucosal healing, which is critical in treating ulcerative colitis. As more healthcare providers seek to personalize treatment plans for patients, Peficitinib's oral administration and favorable side effect profile make it an appealing choice. The rising incidence of ulcerative colitis, coupled with the increasing demand for effective therapeutics, contributes to the anticipated growth of Peficitinib in this application segment. Ongoing clinical studies exploring the drug's long-term benefits and safety in managing ulcerative colitis will further solidify its position in the market.

Crohn's Disease :

Similar to ulcerative colitis, Peficitinib shows potential in the treatment of Crohn's disease, another form of inflammatory bowel disease. The ability of Peficitinib to modify the immune response and reduce inflammation aligns well with the needs of patients suffering from this debilitating condition. The growing recognition of Crohn's disease as a chronic health issue, combined with the need for more effective treatment options, positions Peficitinib favorably in this market. As research unveils the drug's efficacy in managing the symptoms and complications associated with Crohn's disease, healthcare professionals are likely to consider it as a viable treatment option, thereby expanding its application base. The increasing focus on understanding the pathophysiology of Crohn's disease will likely drive further interest in targeted therapies like Peficitinib.

Other Autoimmune Diseases :

Beyond the primary applications, Peficitinib may find utility in treating other autoimmune diseases where JAK signaling plays a critical role. The versatility of Peficitinib allows it to be evaluated for various indications, thus broadening its therapeutic horizons. The growing body of research investigating Peficitinib's effectiveness in conditions such as ankylosing spondylitis, systemic lupus erythematosus, and other inflammatory conditions will contribute to its market expansion. As the medical community continues to explore the potential of Peficitinib in different autoimmune contexts, the overall demand for the product is likely to rise. The emergence of new clinical guidelines embracing the use of JAK inhibitors in treating complex autoimmune conditions could further facilitate market growth in this segment.

By Distribution Channel

Hospital Pharmacies :

Hospital pharmacies serve as a vital distribution channel for Peficitinib, primarily catering to patients undergoing treatment in clinical settings. The ability of hospital pharmacies to provide specialized services, such as compounding and patient education, enhances patient safety and ensures proper medication management. With an increasing number of hospitals adopting integrated care models, the demand for Peficitinib through this channel is projected to grow. Furthermore, the collaboration between pharmaceutical companies and hospitals to improve medication access and optimize prescribing practices contributes to the robust sales of Peficitinib in hospital settings. The comprehensive support offered in hospital pharmacies makes them an essential link in the distribution of Peficitinib, facilitating effective treatment for patients with complex needs.

Retail Pharmacies :

Retail pharmacies represent a significant distribution channel for Peficitinib, providing access to medication for patients managing chronic autoimmune conditions. With the growing trend of self-management and patient empowerment, retail pharmacies are increasingly involved in providing ongoing support for patients, including counseling and medication synchronization. The convenience and accessibility of retail pharmacies facilitate adherence to prescribed treatment regimens, particularly for patients with rheumatoid arthritis and other chronic diseases requiring long-term therapy. The competitive landscape among retail pharmacies, combined with promotional strategies aimed at raising awareness of Peficitinib, is expected to drive its sales through this channel. As patients increasingly seek convenient options to obtain their medications, retail pharmacies will continue to play a crucial role in the distribution of Peficitinib.

Online Pharmacies :

The rise of online pharmacies has transformed the distribution landscape for Peficitinib, offering patients an alternative means of accessing the medication. The convenience and privacy associated with online purchases, especially for individuals managing chronic conditions, drive the demand for Peficitinib through this channel. Online pharmacies often provide competitive pricing and the ability to easily refill prescriptions, further enhancing patient adherence to treatment plans. Additionally, the growing acceptance of telehealth services has led to increased collaboration between healthcare providers and online pharmacies, facilitating the streamlined delivery of Peficitinib to patients in need. As consumer preferences shift towards online shopping for healthcare products, the importance of this distribution channel is expected to grow significantly in the coming years.

By Ingredient Type

Peficitinib :

Peficitinib itself is the sole ingredient type in this market and serves as a potent JAK inhibitor designed to address various autoimmune disorders. The unique mechanism of action of Peficitinib allows it to target specific pathways involved in the inflammatory response, making it an effective treatment option for conditions such as rheumatoid arthritis and ulcerative colitis. As research continues to validate its efficacy and safety, the demand for Peficitinib as a standalone ingredient is expected to rise. Moreover, ongoing studies investigating its potential for new indications will further enhance its profile in the market. The growing emphasis on personalized medicine and targeted therapies ensures that Peficitinib will remain a crucial ingredient type in the treatment of autoimmune diseases.

By Region

The North American region is projected to lead the Peficitinib market, accounting for approximately 45% of the global revenue by 2035. This dominance can be attributed to the high prevalence of autoimmune disorders, advancements in healthcare infrastructure, and significant investments in pharmaceutical research and development. The United States, in particular, is witnessing a surge in demand for innovative therapies as healthcare providers increasingly adopt targeted treatment options to enhance patient outcomes. Additionally, favorable reimbursement policies and a growing emphasis on specialty pharmaceuticals contribute to the robust growth of the Peficitinib market in North America. With a CAGR of around 13% forecasted for this region, the North American market is anticipated to maintain its leading position throughout the forecast period.

Europe is also expected to play a significant role in the growth of the Peficitinib market, representing approximately 30% of the global market share by 2035. The region benefits from a well-established healthcare system and increasing patient awareness regarding autoimmune diseases and available treatment options. Countries like Germany, France, and the United Kingdom are at the forefront of adopting Peficitinib as part of their therapeutic protocols for autoimmune conditions. The European Medicines Agency (EMA) has been actively evaluating and approving new indications for Peficitinib, further enhancing its market potential. The projected CAGR for Europe stands at 10%, reflecting the region's commitment to improving patient access to advanced treatment modalities.

Opportunities

The Peficitinib market offers considerable opportunities for growth, particularly in the realm of expanding indications for use. As ongoing clinical trials continue to explore the efficacy of Peficitinib in treating various autoimmune diseases beyond rheumatoid arthritis, the potential for broader adoption increases. This expansion can lead to a significant rise in patient populations eligible for treatment, thus driving overall sales. Moreover, the increasing demand for personalized medicine offers a unique opportunity for pharmaceutical companies to position Peficitinib as a first-line therapy for patients who do not respond well to traditional treatments, thereby establishing a strong foothold in the market. Additionally, as healthcare systems worldwide continue to prioritize innovative therapies, Peficitinib stands to gain traction in emerging markets where access to advanced treatments is on the rise.

Another significant opportunity presents itself through strategic partnerships and collaborations between pharmaceutical companies and healthcare providers. By fostering relationships with hospitals, clinics, and specialty pharmacies, manufacturers can facilitate better distribution networks and enhance the visibility of Peficitinib. Engaging in educational initiatives aimed at healthcare professionals and patients can further drive awareness and understanding of Peficitinib’s benefits, ultimately leading to increased adoption rates. Additionally, leveraging digital health technologies and telemedicine can enhance patient engagement and adherence to therapy, creating a more favorable environment for Peficitinib's market penetration. The evolving landscape of autoimmune disease management creates ample opportunities for stakeholders to capitalize on the demand for effective, targeted therapies.

Threats

Despite the promising outlook for the Peficitinib market, several threats could impede its growth trajectory. One of the most significant challenges is the presence of alternative therapies, particularly biologics and other JAK inhibitors, which are currently available on the market. As competition intensifies, established players may introduce more advanced formulations or price discounts, potentially affecting Peficitinib’s market share. Furthermore, the stringent regulatory landscape governing drug approvals can pose hurdles for new indications or formulations of Peficitinib, limiting its potential growth avenues. The increasing scrutiny regarding safety profiles of JAK inhibitors, coupled with concerns surrounding long-term use, may also deter healthcare providers from prescribing Peficitinib, affecting demand. Additionally, economic fluctuations and budget constraints within healthcare systems can lead to reduced spending on specialty pharmaceuticals, posing a challenge for Peficitinib’s market performance.

Another critical factor to consider is the potential for adverse events and side effects associated with Peficitinib. Reports of serious complications or unexpected safety concerns may lead to regulatory actions or warnings, ultimately impacting physician prescribing behavior. Furthermore, the evolving landscape of autoimmune disease treatment and the continuous introduction of novel therapies can create uncertainty in market dynamics, as patient preferences shift towards emerging options perceived as more effective or safer. Such shifts could result in decreased market opportunities for Peficitinib. Lastly, the increasing awareness and advocacy surrounding patient access to medications may lead to heightened expectations for affordability and accessibility, placing additional pressure on manufacturers to justify pricing structures amidst rising competition.

Competitor Outlook

• Pfizer Inc.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Amgen Inc.
• Novartis AG
• Sanofi S.A.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Eli Lilly and Company
• Regeneron Pharmaceuticals, Inc.
• Celgene Corporation
• UCB S.A.

The competitive landscape of the Peficitinib market is characterized by a mix of established pharmaceutical giants and emerging players, all vying for market share in this lucrative segment. Major companies such as Pfizer Inc., AbbVie Inc., and Gilead Sciences, Inc. have invested heavily in research and development to enhance their portfolios of autoimmune disease therapies, including JAK inhibitors and biologics. This competition fosters innovation and drives improvements in treatment options available to patients. The landscape is further complicated by rapid advancements in drug technology and delivery systems, as companies strive to distinguish themselves in a crowded marketplace. Moreover, strategic collaborations and partnerships are increasingly common as companies seek to leverage complementary strengths, resulting in a dynamic and evolving competitive environment.

One of the leaders in the Peficitinib market, Pfizer Inc., continues to expand its influence through investments in additional clinical trials aimed at exploring new indications for its autoimmune therapies. The company’s commitment to patient-centric approaches has resulted in innovative treatment solutions that address unmet medical needs. By maintaining a strong pipeline of research initiatives, Pfizer is well-positioned to capitalize on emerging opportunities within the Peficitinib market. Meanwhile, AbbVie Inc., known for its robust portfolio of immunology products, is actively working to enhance patient outcomes through a focus on personalized treatment regimens. The company’s strategic marketing efforts and effective physician engagement initiatives have helped solidify its position in the competitive landscape.

Gilead Sciences, Inc. has also made significant strides in the Peficitinib market, focusing on developing therapies that target complex autoimmune conditions. The company’s commitment to rigorous clinical research and patient safety has enabled it to build a strong reputation in the field. Notably, Gilead is actively exploring opportunities to expand the indications for Peficitinib, thereby broadening its market potential. The competitive strategies employed by these major players, including their ability to adapt to changing market demands and regulatory landscapes, will be critical in shaping the future trajectory of the Peficitinib market. As the landscape continues to evolve, ongoing collaboration and innovation will remain essential for companies to maintain their competitive edge and ensure sustainable growth.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eli Lilly and Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Peficitinib CAS 944118 01 8 Sales Market, By Application
    • 6.1.1 Rheumatoid Arthritis
    • 6.1.2 Psoriatic Arthritis
    • 6.1.3 Ulcerative Colitis
    • 6.1.4 Crohn's Disease
    • 6.1.5 Other Autoimmune Diseases
  • 6.2 Peficitinib CAS 944118 01 8 Sales Market, By Product Type
    • 6.2.1 Tablet
    • 6.2.2 Capsule
    • 6.2.3 Injection
    • 6.2.4 Liquid
  • 6.3 Peficitinib CAS 944118 01 8 Sales Market, By Ingredient Type
    • 6.3.1 Peficitinib
  • 6.4 Peficitinib CAS 944118 01 8 Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Peficitinib CAS 944118 01 8 Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Peficitinib CAS 944118 01 8 Sales market is categorized based on

By Product Type

• Tablet
• Capsule
• Injection
• Liquid

By Application

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ulcerative Colitis
• Crohn's Disease
• Other Autoimmune Diseases

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Peficitinib

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Amgen Inc.
• Novartis AG
• Sanofi S.A.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Eli Lilly and Company
• Regeneron Pharmaceuticals, Inc.
• Celgene Corporation
• UCB S.A.